Time for active surveillance of intermediate-risk disease? (original) (raw)

Prostate cancer

Nature Reviews Urology volume 10, pages 6–8 (2013)Cite this article

Subjects

Active surveillance has become increasingly popular as a management option for localized prostate cancer. Although widely viewed as a means to enable men with low-risk prostate cancer to avoid or defer the effects of whole-gland radical therapy, two new studies demonstrate that it might be a safe approach in intermediate-risk disease.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Bul, M. et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11434.x.
  2. Godtman, R. A., Holmberg, E., Khatami, A., Stranne, J. & Hugosson, J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2012.08.066.
  3. Dahabreh, I. J. et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann. Intern. Med. 156, 582–590 (2012).
    Article PubMed Google Scholar
  4. McVey, G. P. et al. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int. 106, 1161–1164 (2010).
    Article PubMed Google Scholar
  5. Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S. & Carroll, P. R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 22, 2141–2149 (2004).
    Article PubMed Google Scholar
  6. King, M. T. et al. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. Br. J. Cancer 106, 638–645 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  7. Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203–213 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  8. Klotz, L. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28, 126–131 (2010).
    Article PubMed Google Scholar
  9. Ahmed, H. U. et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 13, 622–632 (2012).
    Article PubMed PubMed Central Google Scholar
  10. Ahmed, H. U., Arya, M., Freeman, A. & Emberton, M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 13, e509–e517 (2012).
    Article PubMed Google Scholar

Download references

Author information

Authors and Affiliations

  1. Division of Surgery and Interventional Sciences, University College London, 4th Floor, 74 Huntley Street, London, WC1E 6AU, UK
    Hashim U. Ahmed

Authors

  1. Hashim U. Ahmed
    You can also search for this author inPubMed Google Scholar

Ethics declarations

Competing interests

The author declares that he receives funding from USHIFU for clinical trials and has previously been a paid consultant to Oncura (GE Healthcare).

Rights and permissions

About this article

Cite this article

Ahmed, H. Time for active surveillance of intermediate-risk disease?.Nat Rev Urol 10, 6–8 (2013). https://doi.org/10.1038/nrurol.2012.213

Download citation